Clinical trials: Urinary Complications
Overactive Bladder
FREEDOM - First Real-Life Evaluation of Enablex Done in ZA Overactive Bladder Patients During a 3 Months Period
Patient perspective on Overactive Bladder and symptoms experienced after administration of Darifenacin
- Trial name
- FREEDOM (NCT00921245)
- Testing
- Darifenacin (Emselex, BAY79-4998)
- Where
- South Africa
- Volunteers
- 9 people
- Sponsor
- Bayer
Urinary Tract Cancer
A Study of Herceptin (Trastuzumab) Monotherapy in Patients With Metastatic Urothelial Cancer
This study will evaluate the efficacy and safety of intravenous Herceptin in patients with metastatic urothelial cancer with disease progression during platinum-based chemotherapy.
- Trial name
- NCT02013765
- Testing
- trastuzumab
- Where
- 7 sites in Germany
- Volunteers
- 5 people
- Sponsor
- Hoffmann-La Roche
Urinary Incontinence
Effect Of Detrol LA With Behavioral Intervention In Overactive Bladder Subjects Dissatisfied With Recent OAB Medication.
To evaluate the effect of tolterodine ER in conjunction with behavioral intervention on subject satisfaction in OAB subjects who were dissatisfied with their most recent antimuscarinic OAB medication therapy.
- Trial name
- NCT00230789
- Testing
- Tolterodine ER 4 mg QD, OAB Patient Behavioral Training Material
- Where
- 51 sites in United States
- Volunteers
- 417 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Stress Urinary Incontinence
Vesair Balloon Confirmatory Trial (VECTOR)
Multicenter, prospective, single-arm study to assess the safety and efficacy of the Vesair Bladder Control treatment in post-menopausal women with Stress Urinary Incontinence (SUI) with follow-up at 1, 3 and 12 months.
- Trial name
- VECTOR (NCT03794206)
- Testing
- Vesair Balloon
- Where
- 8 sites in United States
- Volunteers
- 20 people
- Sponsor
- Solace Therapeutics, Inc.
Stress Urinary Incontinence
A Clinical Evaluation of the Tension-Free Vaginal Tape Obturator System For Treatment of Stress Urinary Incontinence (Urinary Leakage)
Stress urinary incontinence affects nearly 30 million women worldwide and the main goal of surgical treatment is to stop urinary incontinence (urinary leakage) that occurs with physical activity, coughing, sneezing, etc.Patients…
- Trial name
- NCT00196521
- Testing
- Tension-free vaginal tape obturator system
- Where
- 19 sites in United States, Canada and 5 more
- Volunteers
- 300 people
- Sponsor
- Ethicon, Inc.
Overactive Bladder, Urinary Incontinence
A Research Study for Patients With Overactive Bladder
The purpose of this study is to investigate whether injections of botulinum toxin Type A into the bladder are safe and effective in treating overactive bladder.
- Trial name
- NCT00168454
- Testing
- botulinum toxin Type A
- Where
- 6 sites in United States, Belgium and 4 more
- Volunteers
- 313 people
- Sponsor
- Allergan
Overactive Bladder, Nocturia
NOGO for an Overactive Bladder
This is a double-blind, randomized and placebo-controlled study to evaluate the safety and effectiveness of NoGo, a standardized extract from Angelica archangelica, on overactive bladder
- Trial name
- NOGO-OAB (NCT04357223)
- Testing
- extract from Angelica archangelica leaf
- Where
- Spain
- Volunteers
- 200 people
- Sponsor
- SagaNatura
Overactive Bladder
Evaluate the Safety and Efficacy of Botulax® Versus Botox® in Patient With Overactive Bladder
To determine the efficacy and safety of Botulax® in treatment of Overactive Bladder
- Trial name
- NCT04186442
- Testing
- Botulinum toxin type A injection, Botulinum Toxin Type A Injection [Botox]
- Where
- South Korea
- Volunteers
- 38 people
- Sponsor
- Hugel
Overactive Bladder (OAB)
Non-invasive Saphenous Nerve Stimulation Therapy for Overactive Bladder
The goal of this clinical trial is to study the NiNA System and how it works to treat overactive bladder. Up to 290 participants will be enrolled in the study in the USA and Australia.
- Trial name
- NOVASTIM (NCT07780786)
- Testing
- Wearable neurostimulation system for saphenous nerve stimulation, tolterodine tartrate 4 mg extended release
- Where
- 2 sites in United States, Australia
- Volunteers
- 290 people
- Sponsor
- NinaMED Pty Ltd
Bladder Cancer, Urothelial Carcinoma
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
The purpose of this study is to measure the effect of IPI-549 in combination with nivolumab when compared to nivolumab monotherapy in advanced urothelial cancer patients.
- Conditions
- Bladder Cancer, Urothelial Carcinoma, Solid Tumor, Advanced Cancer
- Trial name
- NCT03980041
- Testing
- IPI-549 (eganelisib), Nivolumab
- Where
- 29 sites in United States, Czechia and 5 more
- Volunteers
- 49 people
- Sponsor
- Infinity Pharmaceuticals, Inc.
Urinary Bladder, Overactive
Solifenacin Succinate Versus Tolterodine 4mg Once Daily
Prospective, double-blind, double-dummy, 2-arm, parallel-group, design. Flexible dose regimen for solifenacin succinate, fixed dose treatment regimen for tolterodine. Assessment of OAB symptoms by patient diaries.
- Trial name
- STAR (NCT00802373)
- Testing
- Solifenacin succinate, Tolterodine
- Where
- 95 sites in Belarus, Belgium and 15 more
- Volunteers
- 1,355 people
- Sponsor
- Astellas Pharma Inc
Overactive Bladder
An Implantable Microstimulator for the Chronic Treatment of Urinary Urgency-Frequency Syndrome
The goal of this study is to investigate the safety and effectiveness of a new implanted device designed to treat Urinary Urgency-Frequency Syndrome.
- Trial name
- NCT00131573
- Testing
- bion
- Where
- 11 sites in United States
- Volunteers
- 118 people
- Sponsor
- Boston Scientific Corporation
Urothelial Carcinoma, Bladder Cancer
Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab
This is a Phase 2, multicenter, randomized, open-label study evaluating the safety and efficacy of trilaciclib administered with platinum-based chemotherapy followed by trilaciclib administered with avelumab maintenance therapy…
- Conditions
- Urothelial Carcinoma, Bladder Cancer, Myelosuppression Adult, Chemotherapy-induced Neutropenia
- Trial name
- PRESERVE3 (NCT04887831)
- Testing
- Trilaciclib, Gemcitabine, Cisplatin
- Where
- 34 sites in United States, France and 3 more
- Volunteers
- 92 people
- Sponsor
- G1 Therapeutics, Inc.
Neurogenic Urinary Bladder
Alfuzosin Treatment in Children and Adolescents With Neurogenic Urinary Bladder Dysfunction
The primary objective of the study was to evaluate the efficacy of Alfuzosin in comparison to Placebo on the detrusor Leak Point Pressure (LPP) in children and adolescents 2-16 years of age with elevated detrusor LPP of…
- Trial name
- ALFACHIN (NCT00549939)
- Testing
- Alfuzosin
- Where
- 18 sites in United States, Bulgaria and 16 more
- Volunteers
- 172 people
- Sponsor
- Sanofi
Carcinoma, Transitional Cell, Urinary Bladder Neoplasms
A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer
This study will test an experimental drug (enfortumab vedotin) alone and with different combinations of anticancer therapies. Pembrolizumab is an immune checkpoint inhibitor (CPI) that is used to treat patients with cancer of the…
- Conditions
- Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Urologic Neoplasms, Renal Pelvis Neoplasms
- Trial name
- EV-103 (NCT03288545)
- Testing
- enfortumab vedotin (EV), pembrolizumab, cisplatin
- Where
- 106 sites in United States, Canada and 4 more
- Volunteers
- 348 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Urinary Bladder Neoplasms, Neoplasm Metastasis
Expanded Access for Vepugratinib (LY3866288) in Participants With Fibroblast Growth Factor Receptor 3 (FGFR3) Altered Solid Tumors
The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.
- Conditions
- Urinary Bladder Neoplasms, Neoplasm Metastasis, Carcinoma, Transitional Cell
- Trial name
- NCT07675057
- Testing
- Vepugratinib
- Sponsor
- Eli Lilly and Company
Urinary Bladder Neoplasms
A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder
A study to evaluate the safety and tolerability of nivolumab or nivolumab Plus BMS-986205 with or without BCG in BCG-Unresponsive non-muscle invasive Bladder Cancer.
- Trial name
- CheckMate 9UT (NCT03519256)
- Testing
- Nivolumab, BCG, BMS-986205
- Where
- 88 sites in United States, Argentina and 13 more
- Volunteers
- 142 people
- Sponsor
- Bristol-Myers Squibb
Stress Urinary Incontinence
GTx-024 as a Treatment for Stress Urinary Incontinence in Women
The purpose of this study is to determine whether GTx-024 is safe and effective in the treatment of stress urinary incontinence in postmenopausal women.
- Trial name
- NCT02658448
- Testing
- GTx-024
- Where
- 3 sites in United States
- Volunteers
- 19 people
- Sponsor
- GTx
Cancer
Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma
RATIONALE: Intravenous VEGF Trap may stop the growth of solid tumors or non-Hodgkin's lymphoma by stopping blood flow to the cancer.
- Trial name
- NCT00082823
- Testing
- ziv-aflibercept
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Regeneron Pharmaceuticals
Recurrent Urinary Tract Infections in Women
Evaluate the Efficacy and Safety of U101 Oral Capsules in the Prevention of Uncomplicated rUTIs in Women
The goal of this clinical trial is to learn if drug U101 works to prevent recurrent urinary tract infection (rUTI) in women (≥ 20 and < 76 years old) with a medical history.
- Trial name
- U101 (NCT07184827)
- Testing
- U101
- Where
- 18 sites in Taiwan
- Volunteers
- 348 people
- Sponsor
- TCM Biotech International Corp.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.